Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 73Lung Neoplasms 64Breast Neoplasms 63Lymphoma 58Ovarian Neoplasms 51Leukemia 44Sarcoma 43Prostatic Neoplasms 39Multiple Myeloma 36Head and Neck Neoplasms 36Central Nervous System Neoplasms 36Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 31Carcinoma, Ovarian Epithelial 30Melanoma 29Rectal Neoplasms 28Neoplasm Metastasis 27Uterine Cervical Neoplasms 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lymphoma, Large B-Cell, Diffuse 26Brain Neoplasms 26Urinary Bladder Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Leukemia, Myeloid, Acute 23Fallopian Tube Neoplasms 23Endometrial Neoplasms 22Glioblastoma 21Adenocarcinoma of Lung 21Lymphoma, Mantle-Cell 18Gliosarcoma 17

Interventions

tremelimumab 1temsirolimus 1durvalumab 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × Advanced Rare Tumours × Clear all
NCT01396408 2026-03-27

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Active not recruiting
137 enrolled

Advanced Rare Tumours

NCT02879162 2025-03-07

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Completed
140 enrolled 9 charts

Advanced Rare Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡